Anthracycline-induced cardiomyopathy in the long-term period after chemotherapy: clinical case
- Authors: Kozjavin N.A.1, Mureyko E.A.1, Nikiforov V.S.2, Beljaev A.M.1
-
Affiliations:
- Petrov National Medicine Research Center of Oncology
- Mechnikov North-Western State Medical University
- Issue: Vol 13, No 3 (2022)
- Pages: 176-180
- Section: Case reports
- URL: https://journals.rcsi.science/2221-7185/article/view/134175
- DOI: https://doi.org/10.17816/CS133645
- ID: 134175
Cite item
Full Text
Abstract
Background. As is known, the treatment of the oncological process leads either to the occurrence of cardiovascular pathology, or to an increase in the risk of death from cardiovascular diseases. Currently, the concept of ˝cardiovascular toxicity˝ has been introduced, which is associated with the treatment of cancer (CTR-CVT). Systemic drug anthracycline-containing anticancer therapy can cause a number of cardiovascular complications, such as myocardial systolic dysfunction, coronary heart disease, cardiac arrhythmias, arterial hypertension. Particular attention is paid to anthracycline drugs, because they are still included in combinations of many adjuvant therapy regimens and first-line treatment of both the most common cancers and rarer ones.
Clinical Case Description. The article presents a clinical case of a patient who received adjuvant polychemotherapy for breast cancer in 2017 with AC ×4 →D ×4 regimen, in which chronic anthracycline-induced cardiomyopathy manifested years after completion of antitumor therapy. The development of anthracycline cardiomyopathy is possible even in patients with initially low cardiac risk.
Conclusion. The clinical case highlights the importance of monitoring patients after the end of anthracycline antitumor therapy, in particular, they are shown to periodically perform an echocardiographic study in order to detect delayed asymptomatic myocardial dysfunction.
Full Text
##article.viewOnOriginalSite##About the authors
Nikita A. Kozjavin
Petrov National Medicine Research Center of Oncology
Email: kozjavin-nikita@mail.ru
ORCID iD: 0000-0003-2759-4817
department head
Russian Federation, 191015, St. Petersburg, Kirochnaya Str., 41Ekaterina A. Mureyko
Petrov National Medicine Research Center of Oncology
Email: emureyko@mail.ru
ORCID iD: 0000-0003-1626-082X
SPIN-code: 2023-1598
resident oncologist
Russian Federation, 191015, St. Petersburg, Kirochnaya Str., 41Viktor S. Nikiforov
Mechnikov North-Western State Medical University
Email: victor-nikiforov@yandex.ru
ORCID iD: 0000-0001-7862-0937
SPIN-code: 4652-0981
MD, D. Sci. (Med.), Prof., dean
Russian Federation, 41, Kirochnaya Str., St. Petersburg, 191015Alexey M. Beljaev
Petrov National Medicine Research Center of Oncology
Author for correspondence.
Email: bam281060@yandex.ru
ORCID iD: 0000-0001-6588-1257
SPIN-code: 9445-9473
MD, D. Sci. (Med.), Prof., director,
Russian Federation, 191015, St. Petersburg, Kirochnaya Str., 41References
- Pudil R, Mueller C, Celutkiene J, et al. Role of serum biomarkers in cancer patients receiving cardiotoxic cancer therapies: a position statement from the Cardio-Oncology Study Group of the Heart Failure Association and the Cardio-Oncology Council of the European Society of Cardiology. Eur J Heart Fail. 2020;22(11):1966–1983. doi: 10.1002/ejhf.2017
- Сelutkienе J. Pudil R, López-Fernández T, et al. Role of cardiovascular imaging in cancer patients receiving cardiotoxic therapies: a position statement on behalf of the Heart Failure Association (HFA), the European Association of Cardiovascular Imaging (EACVI) and the Cardio-Oncology Council of the European Society of Cardiology (ESC). Eur J Heart Fail. 2020;22(9):1504–1524. doi: 10.1002/ejhf.1957
- Vitsenya MV, Ageev FT, Gilyarov MYu, et al. Practical recommendations for the correction of cardiovascular toxicity of anticancer drug therapy. Malignant tumors. 2019;9(3S2):609–627. (In Russ). doi: 10.18027 / 2224-5057-2019-9-3s2-609-627
- McDonagh TA, Metra M, Adamo M, et al. 2021 ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure. Eur Heart J. 2021;42(36):3599–3726. doi: 10.1093/eurheartj/ehab368
- Cardinale D, Biasillo G, Salvatici M, et al. Using biomarkers to predict and to prevent cardiotoxicity of cancer therapy. Expert Rev Mol Diagn. 2017;17(3):245–256. doi: 10.1080/14737159.2017.1283219
- Chen MH, Colan SD, Diller L. Cardiovascular disease: cause of morbidity and mortality in adult survivors of childhood cancers. Circ Res. 2011;108(5):619–628. doi: 10.1161/CIRCRESAHA.110.224519
- Mann D, Felker G. Heart Failure: A Companion to Braunwald’s Heart Disease. 4th ed. Philadelphia: Elsevier; 2016.
- Cardinale D, Colombo A, Bacchiani G, et al. Early detection of anthracycline cardiotoxicity and improvement with heart failure therapy. Circulation. 2015;131(22):1981–1988. doi: 10.1161/CIRCULATIONAHA.114.013777
- Ryberg M, Nielsen D, Cortese G, et al. New insight into epirubicin cardiac toxicity: competing risks analysis of 1097 breast cancer patients. J Natl Cancer Inst. 2008;100(15):1058–1067. doi: 10.1093/jnci/djn206
- Chazova IE, Ageev FT, Aksenova AV, et al. Eurasian clinical guidelines for cardiovascular complications of cancer treatments: diagnosis, prevention and treatment (2022). Eurasian heart journal. 2022;(1):6–79. (In Russ). doi: 10.38109/2225-1685-2022-1-6-79